Ocular Therapeutix Inc. (NASDAQ: OCUL) Chief Development Officer Peter Kaiser sold 3,035 ordinary shares on August 24, 2026, for approximately $32,686 under an automatic sale plan established in April 2024.
The transaction was executed at weighted average price of $10.77 per share, within a range of $10.6429 to $10.9125. Kaiser’s disposal was not discretionary and was linked to tax withholding obligations tied to the vesting of restricted stock units on August 22, 2026.
Following the sale, Kaiser retains beneficial ownership of 264,378 ordinary shares of Ocular Therapeutix, including 1,272 shares acquired through the company’s Updated 2014 Employee Stock Purchase Plan on June 30, 2026. The stock last traded 34% below its 52-week high of $16.44 and 73% above its 52-week low of $6.23.
Ocular Therapeutix continues to advance its pipeline, with plans to submit a New Drug Application for AXPAXLI in the fourth quarter of 2026, following alignment with U.S. FDA on efficacy and safety requirements. Analysts at H.C. Wainwright raised the company’s price target to $25, while Citizens maintained an Outperform rating with a $34 target, noting second-quarter 2026 Dextenza revenue estimates at $12 million.
Call options volume reached 9,882 contracts. The news follows a competitor’s setback, as EyePoint Pharmaceuticals reported a failed primary endpoint in its wet AMD study.
